Jessica McDonough is a co-founder and VP at Attivare Tx, a new immunotherapy company developing technology from the Wyss Institute at Harvard. Jessica joined Attivare Tx in July of 2021 to develop innovative immunotherapies. Prior to joining Attivare, Jessica in business development roles at the Wyss Institute at Harvard from 2014-2021. Jessica was responsible for translating technologies in the areas of synthetic biology and molecular robotics. Prior to joining Wyss, Jessica worked at Decision Resources (now Clarivate) as a Principal in their custom consulting division. She worked with top pharmaceutical and biotech companies on over fifty engagements including topics such as therapeutic area landscapes, opportunity assessments, and valuations focusing on both the major and emerging markets. Jessica holds a Ph.D. from the Johns Hopkins University School of Medicine in Cellular and Molecular Medicine.
CCS is a nonprofit 501(c)(3) organization. Contributions to CCS are tax deductible to the extent permitted by law. EIN 84-3817744